An interventional study of The DM/DIV ScreenCell is the experimental product studied during this research in Breast Cancer, Metastatic, Breast Cancer Invasive and Breast Cancer Early Stage Breast Cancer (Stage 1-3), sponsored by ScreenCell. Recruiting at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by ScreenCell · Not applicable, Interventional, and Other
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.
The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's planned enrollment of 93 is above the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →This is the only study on the registry with ScreenCell as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For all participants :
For participants with breast cancer:
- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion.
For participants with non-metastatic invasive breast cancer:
- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment)
For healthy volunteers:
EXCLUSION CRITERIA
For all participants:
For healthy volunteers:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with no prior history of cancer and confirmed to be cancer-free at the time of inclusion, as evidenced by a negative mammogram performed within two years before enrollment
Device: The DM/DIV ScreenCell is the experimental product studied during this research
Participants with metastatic breast cancer or metastatic relapse of previously treated breast cancer with change of therapeutic line at the time of study inclusion, confirmed by a POSITIVE PET-Scan
Device: The DM/DIV ScreenCell is the experimental product studied during this research
Participants with invasive breast cancer but non-metastatic, confirmed by PET scan or mammography (confirmation not mandatory)
Device: The DM/DIV ScreenCell is the experimental product studied during this research
The product is not used directly on the subject, but on a blood sample taken from the participant.
Evolution of the kinetics of CTC during treatment
Evolution of the number of CTC isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients. Average number of CTCs measured during the study (D0, W6, W12, W24, W36) with a tolerance of +/- 8 days for the visits
Time frame: From enrollement to the end of follow up at 9 months
Molecular characterisation of CTC
Analysis of the expression of specific antigens and the presence of informative mutations on CTCs isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients during the study (D0, W6, W12, W24, W36)
Time frame: From enrollement to the end of follow up at 9 months
Started Feb 2025 (actual). Primary completion is estimated for Sep 2026, 19 months after the start.
Of 110 industry-sponsored interventional studies with no phase under Breast Neoplasms, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 74. This study's planned 19 months is below that.
Counting every sponsor, half of 2,771 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.